Elevated exhaled nitric oxide in anaphylaxis with respiratory symptoms  by Nakamura, Yoichi et al.
lable at ScienceDirect
Allergology International 64 (2015) 359e363Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tOriginal articleElevated exhaled nitric oxide in anaphylaxis with respiratory
symptoms
Yoichi Nakamura a, *, Yoko Hashiba a, Jyunji Endo a, Masashi Furuie a, Atsushi Isozaki a,
Kei-ichi Yagi b
a Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan
b Emergency Medical Care Center, Yokohama City Minato Red Cross Hospital, Kanagawa, Japana r t i c l e i n f o
Article history:
Received 3 September 2014
Received in revised form
23 April 2015
Accepted 1 May 2015
Keywords:
Anaphylaxis
Asthma
FeNO
Nitric oxide
NOS
Abbreviations:
FeNO, fractional exhaled nitric oxide;
iNOS, inducible nitric oxide synthase* Corresponding author. Medical Center for Alle
Yokohama City Minato Red Cross Hospital, 3-12-
Yokohama, Kanagawa 231-8682, Japan.
E-mail address: nakamura.alle@yokohama.jrc.or.jp
Peer review under responsibility of Japanese Soci
http://dx.doi.org/10.1016/j.alit.2015.05.005
1323-8930/Copyright © 2015, Japanese Society of Alle
licenses/by-nc-nd/4.0/).a b s t r a c t
Background: Anaphylaxis is a serious type I allergic reaction that occurs suddenly and can result in death,
but it is sometimes difﬁcult to differentiate from other diseases, and physicians must rely on symptoms
alone for its diagnosis. Meanwhile, fractional exhaled nitric oxide (FeNO) concentration, used in assessing
airway inﬂammation in bronchial asthma, is known to be affected by atopic disposition. The possible role
of FeNO measurements was evaluated in patients with anaphylaxis.
Methods: FeNO was measured in 52 adult patients (17e78 years old, median age 41.5 years) in whom
anaphylaxis occurred. These measurements were made within 24 h after onset and after about one
month when the patients were symptom-free. In some of these patients, FeNO was measured a third
time, two months or more after onset.
Results: The FeNO level in the 52 patients was not signiﬁcantly different in measurement made within
24 h of onset of anaphylaxis and after one month. However, excluding 9 patients who also had asthma
history, the FeNO level in the remaining 43 patients decreased signiﬁcantly from within 24 h of onset
(36.7 ± 27.5 ppb) to one month later (28.8 ± 19.5 ppb). Of these 43 patients, this phenomenon was
evident in a group that had respiratory symptoms (31 patients), but it was not seen in a group that did
not have respiratory symptoms (12 patients).
Conclusions: Elevation of FeNO was related to respiratory symptoms observed in anaphylactic patients
without asthma. Although the mechanism of increased FeNO level is unclear, its usefulness for diagnosis
of anaphylaxis must be examined in prospective studies.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Anaphylaxis is a severe allergic reaction that occurs rapidly and
can lead to death, and early diagnosis and treatment affect out-
comes. However, anaphylaxis is sometimes difﬁcult to differentiate
from an asthmatic attack, fainting, anxiety/panic disorder, acute
urticaria, and other conditions, and there are no diagnostic criteria
about which there is consensus. In clinical practice, clinical diag-
nostic criteria based on medical interview responses andrgic and Immune Diseases,
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ety of Allergology.
rgology. Production and hosting by Elsecharacteristic symptoms established by the World Allergy Organi-
zation (WAO) are used.1 However, excluding cases for which there
is an obvious time relationship between symptoms and exposure to
a causative agent, such as a bee sting or a speciﬁc immunotherapy,
or when anaphylaxis occurs after exposure to a known allergen for
that patient, physicians must currently rely on symptoms alone for
diagnosis of anaphylaxis in situations when this information
cannot be obtained.
Fractional exhaled nitric oxide (FeNO) concentration, used in
assessing airway inﬂammation in bronchial asthma, is known to be
affected by atopic disposition, rhinitis, smoking, and other con-
ditions.2e4 Focusing both on the fact that atopic disposition affects
FeNO production and that the basic pathology of anaphylaxis is an
allergic reaction (immediate allergy) via IgE antibodies, the possible
utility of FeNO measurements in anaphylaxis was investigated in
this study.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Charcteristics of patients with anaphylaxis whose FeNO were measured both in acute phase and stable phase.
Case Gender Age Allergen Asthma
history
Current treatment
for asthma
Current
smoking
Serious symptom Treatment for
anaphylaxis
FeNO (ppb)
Lower
airway
symptom
Hypotension Gradey Adrenaline Steroid Acute
phase
Stable
phase
1 F 50 WDEIAnz    þ  Moderate   17 19
2 M 62 WDEIAn      Severe  þ 24 31
3 F 29 Oral mitex   þ þ  Moderate   36 32
4 M 65 Venom    þ þ Severe þ þ 34 54
5 F 31 Soybean or nuts    þ  Moderate   16 12
6 F 19 Unknown drug    þ þ Severe  þ 10 11
7 M 47 Wheat    þ  Moderate   63 35
8 M 25 Anisakis   þ þ  Moderate  þ 20 16
9 M 45 NSAID¶   þ þ  Moderate þ þ 108 43
10 F 34 Nuts      Mild   23 18
11 F 63 Shrimp     þ Severe þ þ 28 36
12 F 49 Wheat    þ  Severe þ þ 29 46
13 M 39 Butterbur sprout   þ þ  Moderate þ þ 45 22
14 M 58 Bamboo shoot      Moderate  þ 35 35
15 M 31 Unknown   þ þ  Moderate   25 29
16 M 45 Anisakis    þ  Moderate þ þ 20 15
17 F 68 Anisakis     þ Severe  þ 11 11
18 M 40 Egg    þ  Moderate þ þ 82 49
19 F 36 NSAID   þ þ  Moderate þ þ 14 9
20 F 33 Anisakis   þ  þ Severe þ þ 14 8
21 F 20 Wheat    þ þ Severe  þ 21 14
22 F 47 Anisakis    þ  Moderate þ þ 45 21
23 M 49 NSAID    þ  Moderate þ þ 56 59
24 F 57 Unknown      Mild  þ 17 13
25 F 73 Mushroom    þ  Moderate þ þ 21 14
26 M 17 Shrimp    þ  Moderate þ  71 69
27 F 54 NSAID   þ þ  Moderate  þ 37 28
28 M 53 Shrimp      Moderate  þ 42 32
29 F 41 Buchwheat      Moderate þ þ 13 17
30 M 33 Apple   þ þ  Moderate þ þ 28 22
31 M 37 Soybean    þ  Moderate þ þ 82 66
32 F 47 Mackerel    þ  Moderate  þ 44 23
33 F 25 Unknown      Moderate   21 13
34 F 42 Antibiotics    þ  Moderate þ þ 137 35
35 F 25 Sea urchin    þ  Severe þ  13 16
36 F 55 Shrimp    þ  Moderate þ þ 37 50
37 M 54 Spirinchus
lanceolatus
   þ þ Severe þ þ 5 5
38 F 24 Wheat    þ  Moderate   63 22.4
39 F 38 Unknown    þ  Moderate þ þ 16 15
40 M 61 Antibiotics    þ  Moderate þ  26 25
41 F 30 Shrimp      Mild þ þ 53 101
42 M 21 Nuts      Mild þ þ 19 17
43 M 42 WDEIAn    þ þ Severe þ þ 58 28
44 F 52 Anisakis þ FPk(200) 4puff  þ  Moderate   49 52
45 M 43 NSAID þ FP(250)/SM# (25) 2puff  þ  Moderate  þ 25 34
46 M 41 WDEIAn þ No þ þ þ Severe  þ 15 26
47 F 47 Shrimp þ BUD(160)/FMyy(4.5) 2puff   þ Severe þ þ 23 22
48 F 21 Spawn þ No þ  þ Severe þ þ 42 117
49 F 36 Tuna þ No þ þ  Moderate þ þ 30 14
50 F 34 Supplement
drug
þ No þ  þ Severe þ þ 31 34
51 F 78 NSAID þ BDPzz(100) 2puff  þ þ Severe  þ 37 26
52 M 17 WDEIAn or
tomato
þ no  þ þ Severe þ þ 115 183
y Based on reference 6.
z Wheat dependent exercise induced anaphylaxis.
x Mite-contaminated foods.
¶ Non-steroidal anti-inﬂammatory drug.
k Fluticasone propionate.
# Salmeterol.
yy Formoterol.
zz Beclomethasone.
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Fig. 1. FeNO levels in 42 patients of anaphylaxis without asthma history at acute phase
and stable phase. Bars show mean ± SD.
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Subjects
The investigation was done with 52 adult anaphylaxis patients
being diagnosed by World Allergy Organization anaphylaxis
guidelines5 treated at the Allergy Center or Emergency Medical
Care Center at the Yokohama City Minato Red Cross Hospital in
whom FeNO levels could be measured within 24 h of onset of
anaphylaxis and after about one month of onset when patients had
no symptoms. Characteristics of all participants of this study was
shown in Table 1. The patients' mean age was 42.0 years (17e78
years, median age 41.5 years), and they had a male-female ratio of
11:15. Nine of the 52 patients (15.4%) also had bronchial asthma.
The severity of the anaphylaxis6 was mild, with skin and mucosal
symptoms, in 3 patients (5.8%), moderate, presenting with respi-
ratory, circulatory, and gastrointestinal symptoms, in 32 patients
(61.5%), and severe, with cyanosis, impaired consciousness, incon-
tinence, and other conditions, in 17 patients (32.7%). FeNO could beFig. 2. A. FeNO levels in 30 patients of anaphylaxis associated with lower airway symptoms
FeNO levels in 12 patients of anaphylaxis without any lower airway symptoms or asthma hmeasured a third time, two months or more after onset of
anaphylaxis, in some patients.
Measurement of FeNO levels
FeNO levels were measured with an expiratory ﬂow rate of
50 mL/s using a NIOX-MINO (Aerocrine AB, Solna, Sweden). Mea-
surements within 24 h of onset were made after the anaphylactic
symptoms had improvedwith treatment. The secondmeasurement
was, as a general rule, made when the patients visited the hospital
again for a detailed examination of the cause of the anaphylactic
symptom episode, about one month after it occurred.
Statistical analysis
All the data were expressed by mean ± SD. Statistical analysis
was done with SPSS ver. 21 (IBM Japan, Tokyo), with p < 0.05 taken
to be a signiﬁcant difference. Investigation of two paired groups
was done with Wilcoxon's signed rank test.
Ethics
This study was approved by the Ethics Committee of Yokohama
City Minato Red Cross Hospital (IRB approval number: 2014-27).
FeNO samples were collected with patients' informed consent.
Results
The FeNO level in all 52 patients showed a tendency to decrease,
from 37.4 ± 27.6 ppb within 24 h after the onset of anaphylaxis to
33.5 ± 30.4 ppb after one month, but the difference was not sig-
niﬁcant. Since complication of bronchial asthma can affect FeNO
level, 43 cases without asthma history were compared with 9 cases
with asthma history. As shown in Fig. 1, the FeNO level decreased
signiﬁcantly in these 43 cases from within 24 h after onset
(36.7 ± 27.5 ppb) to one month later (28.8 ± 19.5 ppb) (p ¼ 0.008).
In the 9 cases with asthma history, the FeNO level was
40.8 ± 29.7 ppb within 24 h of onset and 56.4 ± 56.5 ppb after one
month, and it showed no signiﬁcant changes. Then, all analysis of
afterward was carried out about the 43 cases without asthma his-
tory. In the 43 cases, the FeNO levels in 33 cases whose FeNO was
measured a third time two months or more after the onset ofbut without asthma history at acute phase and stable phase. Bars show mean ± SD. B.
istory at acute phase and stable phase. Bars show mean ± SD.
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25.6 ± 14.5 ppb after one month, and 23.5 ± 14.4 ppb after two
months or more. There was no signiﬁcant difference between the
FeNO levels at one month and two months or more after onset. In
an analysis by level of severity in the 43 cases without asthma
history, a signiﬁcant decrease was seen in FeNO the onset period of
24 h and after one month (mean 28.4 days after onset) only in
moderate cases (n ¼ 28). No signiﬁcant changes were seen in the
severe cases (n ¼ 11), and the number of mild cases (n ¼ 4) was too
small for analysis. Focusing on respiratory symptoms, which were
the main symptoms in the moderate patients, those with and
without respiratory symptoms were compared, and it was found
that, in the group with respiratory symptoms (n ¼ 31), FeNO levels
decreased signiﬁcantly from 41.3 ± 30.4 ppbwithin 24 h of onset to
29.2 ± 17.3 ppb after one month (p ¼ 0.005) (Fig. 2A), whereas in
the group without respiratory symptoms (n ¼ 12), no signiﬁcant
change was seen in the FeNO level, which was 25.0 ± 12.7 ppb
within 24 h of onset and 27.7 ± 25.1 ppb after one month (Fig. 2B).
In addition, FeNO levels at acute phase in comparison with stable
phase was signiﬁcantly high in the cases treated with systemic
corticosteroid (p ¼ 0.042, n ¼ 32) but was not in the cases with
adrenaline injection (n ¼ 25), suggesting that systemic corticoste-
roid and adrenaline may affect FeNO in a different way. In concern
of current smoking, elevated FeNO level was seen even in the cases
with current smokers.
Discussion
Anaphylaxis needs to be differentiated from various diseases for
its diagnosis.5 Peripheral blood tryptase and histamine, which
reﬂect the pathology of a patient, are measured for the purpose of
diagnosing anaphylaxis, but conditions inwhich obvious elevations
in these substances are seen are anaphylaxis from bee stings or
drugs and serious conditions in which decreased blood pressure
occurs. In anaphylaxis due to food allergies or in conditions that do
not result in decreased blood pressure, obvious elevations in
tryptase and histamine are not seen, so that changes need to be
judged over time.6 In other words, these measurements are useful
in severe anaphylaxis in which diagnosis is easy, but their useful-
ness declines in patients whose diagnosis is unclear, and sensitivity
can be considered a major problem. Thus, the diagnosis of
anaphylaxis must still depend on symptoms, and the development
of a simple diagnostic marker is awaited.
In this study, it was found that the FeNO level measured within
24 h of onset in anaphylaxis patients, excluding those with con-
current bronchial asthma, was signiﬁcantly higher than levels
during the stable phase after one month or more had passed from
the acute phase, after which a constant level was maintained. This
result strongly suggests that, although FeNO levels at normal times
before the onset of anaphylaxis are unknown, the change in the
FeNO level is related to the pathology of anaphylaxis. As mentioned
above, there are currently no pathological markers for which re-
sults can be obtained simply and in a short time and that can be
used in clinical practice. It is impossible to examine the sensitivity
and speciﬁcity of FeNO for diagnosis of anaphylaxis, because we
had not measured FeNO with the control cases who visited us as
suspicious anaphylaxis but were diagnosed as other diseases.
Nonetheless, it is possible that measurement of FeNO levels may
become a surrogate marker of diagnosing anaphylaxis accompa-
nied with lower respiratory symptoms. That these changes are
seen, and that the FeNO level is elevated in the acute phase of
anaphylaxis in patients with respiratory symptoms alone, is a
plausible result considering that the airway is the source of FeNO.
Nitric oxide (NO) is known to be produced from airway
epithelial cells and macrophages. It is produced physiologicallyeven in healthy people, but in bronchial asthma, the expression of
inducible nitric oxide synthase (iNOS) from stimulation of inﬂam-
matory cytokines and other substances increases, large amounts of
NO are produced, and respiratory levels rise.7 In addition to airway
epithelial cells and macrophages, NOS is expressed in vascular
endothelial cells, platelets, mast cells, renal epithelium, and the
hippocampus in the brain. Induced NO plays important roles in
various diseases, but in anaphylaxis, it is thought to contribute to
making the pathology more severe via vasodilation.8 Cauwels
et al.,9 using a murine model of anaphylaxis induced by platelet
activating factor (PAF), reported that NO plays a central role in the
pathology of anaphylaxis since NG-nitro-L-arginine methyl ester (L-
NAME), a NOS inhibitor, completely prevented the death of the
mice. Since anaphylaxis is a systemic allergic reaction, there is a
sufﬁcient likelihood that expression of iNOS is increased in airway
epithelium together with vascular endothelium, and expression of
iNOS draws attention as the causes of the rise in FeNO in the acute
phase of anaphylaxis shown in this study. Sade et al.10 analyzed the
expression of iNOS and endothelial nitric oxide synthase (eNOS) in
a mouse model of anaphylaxis using PCR and immunohistochem-
istry. Results was a significant increase in iNOS mRNA expression
andNO production as early as 10e30min after allergen challenge in
both heart and lungs, while the expression of eNOS mRNA was not
altered during the course of the experiment, indicating an
involvement of iNOS in the immediate physiological response of
anaphylaxis.
In concern of elevated FeNO in this study, there remains the
possibility of subclinical/undiagnosed asthma even if asthma his-
tories were denied by interview. We measured airway hyper-
responsiveness of only two participants of the study (case 43 and
52 in Table 1). One patient (case 43) without asthma history
showed FeNO elevation at acute phase of anaphylaxis, and Asto-
graph® being performed two months after anaphylactic episode
revealed no airway hyper-responsiveness. Another severe
anaphylactic patient (case 52) with asthma history in his infant
period, whose FeNO level was high but did not alter during the
following period, showed a potent airway hyper-responsiveness.
Thus, the presence of subclinical/undiagnosed asthma must be
ascertained by the test of airway hyper-responsiveness in all
anaphylactic patients to examine the pathogenesis of elevated
FeNO levels in acute phase of anaphylaxis in future studies.
A deﬁnitive diagnosis of anaphylaxis is important not only in the
acute phase but also in relation to preventing subsequent recur-
rence. Despite later detailed examinations of causes, the allergen
cannot be identiﬁed in a certain percentage of anaphylaxis patients.
In these patients, the course is observed without ever knowing for
certain whether the acute phase episode was actually anaphylaxis.
The FeNO measurements described herein can be easily performed
even during anaphylaxis except in patients with impaired con-
sciousness. In conclusion, although the mechanism of increased
level of FeNO is unclear and its role in pathogenesis is unknown, its
usefulness for diagnosis of anaphylaxis must be examined in pro-
spective studies.
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